COMMUNIQUÉS West-GlobeNewswire

Cannara Announces Graduation to the Toronto Stock Exchange
26/02/2026
MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Cannara annonce son entrée à la Bourse de Toronto
26/02/2026
MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
26/02/2026
TEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s [...]
Addgene Appoints Greg Crescenzi as Vice President of Global Commercial Strategy and Partnerships
26/02/2026
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Addgene, an organization committed to accelerating discovery and innovation by providing a vast catalog of expertly curated and quality-controlled research tools [...]
Mixie Technologies, Inc. (OTC: PHCG) Secures Minority Ownership Stake in Mixie Realty LLC
26/02/2026
Transaction expands Mixie’s platform strategy into immersive real estate visualization and technology-enabled property management DENVER, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mixie Technologies, Inc. (OTC: PHCG), formerly [...]
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
Conference call today at 9:00 am ET Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza ® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $ [...]
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
26/02/2026
Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational discipline Strong revenue outlook, procedure growth, expanding [...]
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin [...]
Cronos Group Reports 2025 Fourth Quarter and Full-Year Results
26/02/2026
Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million ; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025 Eighth consecutive [...]
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
26/02/2026
JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
26/02/2026
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the [...]
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
26/02/2026
Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 [...]
Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call
26/02/2026
ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its fourth quarter and full year results before the market open on [...]
Enovis Announces Fourth Quarter and Full Year 2025 Results
26/02/2026
Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 [...]
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
26/02/2026
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA [...]
Invitation to the 2026 Annual General Meeting
26/02/2026
The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the [...]
Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year 2025 Net Cash [...]
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
26/02/2026
Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2, [...]
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
26/02/2026
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter [...]

Pages